Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases

European Journal of Oncology Nursing

Volumn 12, Issue 4, 2008, Pages 283-290

  Lindqvist, Olav ^a   Rasmussen, Birgit H ^a   Widmark, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Fatigue; Hormone refractory prostatic neoplasm; Pain; Quality of life; Questionnaires and interviews; Skeletal metastases; Symptoms

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ARTICLE; BONE TUMOR; DRUG RESISTANCE; FATIGUE; HUMAN; MALE; METASTASIS; MIDDLE AGED; PAIN; PATHOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; SWEDEN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FATIGUE; HUMANS; MALE; MIDDLE AGED; PAIN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SWEDEN;

EID: 50249154785     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2008.03.003     Document Type: Article

References (27)

1. Armstrong T.S. Symptoms experience: a concept analysis. Oncology Nursing Forum 30 4 (2003) 601-606
2. Bonomi A.E., Cella D.F., Hahn E.A., Bjordal K., Sperner-Unterweger B., Gangeri L., Bergman B., Willems-Groot J., Hanquet P., and Zittoun R. Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Quality of Life Research 5 3 (1996) 309-320
3. Bowling A. Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. second ed (2001), Open University Press, Buckingham
4. Cancer Incidence in Sweden 2005, 2007. Centre for Epidemiology. The National Board of Health and Welfare. Official statistics of Sweden. Health and diseases 2007:3. Published at 〈http://www.socialstyrelsen.se/Statistik/statistik_amne/Cancer〉 (1.03.07).
5. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., Silberman M., Yellen S.B., Winicour P., Brannon J., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 11 3 (1993) 570-579
6. Chapple A., and Ziebland S. Prostate cancer: embodied experience and perceptions of masculinity. Sociology of Health and Illness 24 6 (2002) 820-841
7. Clark J.A., Wray N., Brody B., Ashton C., Giesler B., and Watkins H. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Social Science and Medicine 45 8 (1997) 1299-1309
8. Esper P., and Redman B.G. Supportive care, pain management, and quality of life in advanced prostate cancer. Urologic Clinics of North America 26 2 (1999) 375-389
9. Esper P., Mo F., Chodak G., Sinner M., Cella D., and Pienta K.J. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology [Computer File] 50 6 (1997) 920-928
10. Goodin S., Rao K.V., and DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. The Oncologist 7 4 (2002) 360-370
11. Harden J., Schafenacker A., Northouse L., Mood D., Smith D., Pienta K., Hussain M., and Baranowski K. Couples' experiences with prostate cancer: focus group research. Oncology Nursing Forum 29 4 (2002) 701-709
12. Heidenreich A., von Knobloch R., and Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. European Urology 39 2 (2001) 121-130
13. Jakobsson L., Hallberg I.R., and Loven L. Experiences of daily life and life quality in men with prostate cancer. An explorative study. Part I. European Journal of Cancer Care: the Official Journal of the European Oncology Nursing Society 6 2 (1997) 108-116
14. Lindqvist O., Widmark A., and Rasmussen B.H. Reclaiming wellness-living with bodily problems, as narrated by men with advanced prostate cancer. Cancer Nursing 29 4 (2006) 327-337
15. Navon L., and Morag A. Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties. Qualitative Health Research 13 10 (2003) 1378-1392
16. Navon L., and Morag A. Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer. Social Science and Medicine 58 11 (2004) 2337-2347
17. Nordstedts fackordböcker, 1998. Nordstedts fackordböcker. Medicine, Engelsk-svensk-engelsk (Medicine, English-Swedish-English) (Swedish). Norstedts Ordbok AB, Stockholm.
18. Oh W.K., and Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. Journal of Urology 160 4 (1998) 1220-1229
19. Oliffe J. Embodied masculinity and androgen deprivation therapy. Sociology of Health and Illness 28 4 (2006) 410-432
20. Penson D.F., and Litwin M.S. The physical burden of prostate cancer. Urologic Clinics of North America 30 2 (2003) 305-313
21. Saad F., Clarke N., and Colombel M. Natural history and treatment of bone complications in prostate cancer. European Urology 49 3 (2006) 429-440
22. Sandelowski M. Combining qualitative and quantitative sampling, data collection, and analysis techniques in mixed-method studies. Research in Nursing and Health 23 3 (2000) 246-255
23. Sandelowski M. Whatever happened to qualitative description?. Research in Nursing and Health 23 4 (2000) 334-340
24. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA: Journal of the American Medical Association 294 2 (2005) 238-244
25. Stone P., Richards M., and Hardy J. Fatigue in patients with cancer. European Journal of Cancer 34 11 (1998) 1670-1676
26. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., and Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351 15 (2004) 1502-1512
27. Zubrod C.G., Schneiderman M., Frei E., Brindley C., Gold G.L., Shnider B., Oveido R., Gorman J., Jones R., Jonsson U., Colsky J., Chalmers T., Ferguson B., Dederick M., Holland J., Selawry O., Regelson W., Lasagna L., and Owens A.H. Appraisal or methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Journal of Chronic Diseases 11 (1960) 7-33